Novozymes A/S (OTCMKTS:NVZMY) Shares Gap Down – What’s Next?

Novozymes A/S (OTCMKTS:NVZMY)’s share price gapped down before the market opened on Friday . The stock had previously closed at $70.31, but opened at $66.58. Novozymes A/S shares last traded at $68.72, with a volume of 1,967 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on NVZMY shares. Zacks Research raised shares of Novozymes A/S from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Kepler Capital Markets raised Novozymes A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy”.

Novozymes A/S Stock Down 3.0%

The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.03 and a current ratio of 1.67. The company’s fifty day moving average is $65.89 and its 200-day moving average is $61.27. The company has a market capitalization of $28.27 billion, a PE ratio of 43.16, a price-to-earnings-growth ratio of 3.12 and a beta of 0.93.

Novozymes A/S (OTCMKTS:NVZMY) last issued its quarterly earnings data on Thursday, August 20th. The biotechnology company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.16). Novozymes A/S had a return on equity of 6.60% and a net margin of 14.70%.The business had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.27 billion. As a group, analysts predict that Novozymes A/S will post 2.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Novozymes A/S

A hedge fund recently raised its position in Novozymes A/S stock. Elefante Mark B lifted its position in shares of Novozymes A/S (OTCMKTS:NVZMY) by 73.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,900 shares of the biotechnology company’s stock after acquiring an additional 2,500 shares during the quarter. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors and hedge funds.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).